Abstract
Introduction
The inflammatory bowel disease market is set to grow from $2.9 billion in 2008
to $4.5 billion in 2018 across the seven major markets. While Datamonitor' s
updated forecast will parallel its previous forecast up to 2012, several new
product launches, regional expansion and upgraded brand forecast will help to
sustain growth in the second half of the forecast period.
Key reasons to purchase this research
- Understand how new brands Lialda and Apriso will fare against established
market players, such as Asacol and Pentasa
- Assess the impact of the launch of Cimzia' s recent pre-filled syringe and
gauge future dynamics within the anti-TNF class
- Quantify the current and future size of the inflammatory bowel disease
market
| 
View Cart
